See more : Cherry Hill Mortgage Investment Corporation (CHMI) Income Statement Analysis – Financial Results
Complete financial analysis of Institute of Biomedical Research Corp. (MRES) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Institute of Biomedical Research Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Ennoconn Corporation (6414.TW) Income Statement Analysis – Financial Results
- Spirit Airlines, Inc. (SAVE) Income Statement Analysis – Financial Results
- Rohto Pharmaceutical Co.,Ltd. (RPHCF) Income Statement Analysis – Financial Results
- Authentic Holdings, Inc. (GFTX) Income Statement Analysis – Financial Results
- Santander Consumer USA Holdings Inc. (SC) Income Statement Analysis – Financial Results
Institute of Biomedical Research Corp. (MRES)
About Institute of Biomedical Research Corp.
Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. The company also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators. In addition, it develops and commercializes microbicidal agents; disinfectant products; bandages for large burns, hard surface disinfection, microbicidal treatment of fabrics and textile products, insecticides against bed bugs and other textile goods, microbicidal towels, and mouthwash products; Purilair, an appliance that sterilizes compressed air circulating within medical instruments; colloidal silver and electro medical devices; and BioStim INF that is used for edema reduction, pain relief, and total treatment. Further, the company provides quality control, regulatory, healthcare, environmental services, environmental analysis, building decontamination, and environmental protection and management services; and regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada.
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 1.25M | 786.11K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -1.25M | -786.11K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.34K | 20.66K | 147.78K | 0.00 | 92.90K | 0.00 | 0.00 |
| General & Administrative | 230.93K | 374.14K | 3.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 888.00 | 3.99K | 44.52K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 231.81K | 378.12K | 3.92M | 33.38K | 40.14K | 14.34K | 11.10K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 261.73K | 426.80K | 4.08M | 33.38K | 133.75K | 14.34K | 11.10K |
| Cost & Expenses | 261.73K | 426.80K | 5.33M | 819.48K | 133.75K | 14.34K | 11.10K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.68K | 16.49K | 35.65K | 0.00 | 5.12K | 6.04K | 4.00K |
| Depreciation & Amortization | 22.58K | 28.01K | 11.28K | -22.00 | 713.00 | -239.00 | -371.00 |
| EBITDA | -239.15K | -239.15K | -398.78K | -5.32M | -95.03K | -14.58K | -11.47K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -261.73K | -426.80K | -5.37M | -819.48K | -133.75K | -14.34K | -11.10K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -11.68K | -11.68K | 35.65K | 0.00 | -693.82K | -5.80K | -3.63K |
| Income Before Tax | -273.40K | -443.29K | -5.37M | -827.57K | 176.88K | -20.14K | -14.73K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 23.35K | 32.99K | 71.30K | -129.16K | 43.13K | 6.04K | 4.00K |
| Net Income | -273.40K | -443.29K | -5.37M | -690.30K | -176.88K | -20.14K | -14.73K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | -0.09 | -1.88 | -0.39 | -0.13 | -0.02 | -0.01 |
| EPS Diluted | -0.05 | -0.09 | -1.88 | -0.39 | -0.13 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 5.31M | 4.75M | 2.86M | 1.76M | 1.33M | 1.03M | 1.03M |
| Weighted Avg Shares Out (Dil) | 5.40M | 4.75M | 2.86M | 1.76M | 1.33M | 1.03M | 1.03M |
MRES: M2MMA Gears Up for a Landmark Year in 2024
MRES: M2Bio Sciences Expands Global Presence with New Offices in Dubai Science Park
MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office
African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair
M2MMA Announces 2024 Fight Schedule and Appoints CEO
M2Bio Sciences Chair, Prof Maharaj, to Deliver Keynote Address on Cutting-Edge Biotechnology Advancements
M2Bio Sciences Closes JDAX Acquisition
M2Bio Sciences Pharmacology & Clinical Application of CBD
M2Bio-Discovery Centre for AI-Driven Phytomedicine Research: Update
M2bio Sciences Announces Launch of Exclusive MMA Organization
Source: https://incomestatements.info
Category: Stock Reports